TY - JOUR
T1 - Standardization, workforce development and advocacy in cell and gene therapies
T2 - a summary of the 2020 Regenerative Medicine InterCHANGE
AU - McNiece, Ian K.
AU - Wacker, Kara K.
AU - Kurtzberg, Joanne
AU - Warkentin, Phyllis I.
N1 - Funding Information:
No funding was received. The authors have no commercial, proprietary or financial interest in the products or companies described in this article. Conception and design of the study:. Acquisition of data:. Analysis and interpretation of data:. Drafting or revising the manuscript:. All authors have approved the final article. FACT thanks the participants of the Regenerative Medicine InterCHANGE for their contributions to the fields of cellular therapy and regenerative medicine, for their collaborative spirit in increasing access to patients and for participating in the InterCHANGE. A full list of participating organizations and a description of each can be found in the supplementary material.
Publisher Copyright:
© 2021
PY - 2021/10
Y1 - 2021/10
N2 - Cell and gene therapy is a promising and disruptive new field of medicine for diseases lacking effective treatments. Collaboration among stakeholders has become critically important as investigators, health care providers, manufacturers, couriers, data registries, regulators and payers all become more invested in the success of this field. Many organizations have collaborated with each other to increase clarity, advocate for improvements and share lessons learned. These efforts appear to be making an impact, although the potential for duplicative efforts could slow progress. The second Regenerative Medicine InterCHANGE, hosted by the Foundation for the Accreditation of Cellular Therapy, took place at the Phacilitate Leaders World/World Stem Cell Summit conference in Miami, Florida, on January 24, 2020. Participants from several organizations outlined needs to advance cell and gene therapies. Efforts to address these include standardization, workforce development and advocacy. This article summarizes the major challenges and opportunities discussed during the InterCHANGE.
AB - Cell and gene therapy is a promising and disruptive new field of medicine for diseases lacking effective treatments. Collaboration among stakeholders has become critically important as investigators, health care providers, manufacturers, couriers, data registries, regulators and payers all become more invested in the success of this field. Many organizations have collaborated with each other to increase clarity, advocate for improvements and share lessons learned. These efforts appear to be making an impact, although the potential for duplicative efforts could slow progress. The second Regenerative Medicine InterCHANGE, hosted by the Foundation for the Accreditation of Cellular Therapy, took place at the Phacilitate Leaders World/World Stem Cell Summit conference in Miami, Florida, on January 24, 2020. Participants from several organizations outlined needs to advance cell and gene therapies. Efforts to address these include standardization, workforce development and advocacy. This article summarizes the major challenges and opportunities discussed during the InterCHANGE.
KW - advocacy
KW - cellular therapy
KW - collaboration
KW - regenerative medicine
KW - standardization
KW - workforce
UR - http://www.scopus.com/inward/record.url?scp=85103279691&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103279691&partnerID=8YFLogxK
U2 - 10.1016/j.jcyt.2021.02.004
DO - 10.1016/j.jcyt.2021.02.004
M3 - Article
C2 - 33775525
AN - SCOPUS:85103279691
SN - 1465-3249
VL - 23
SP - 886
EP - 893
JO - Cytotherapy
JF - Cytotherapy
IS - 10
ER -